Last reviewed · How we verify
NCT04295330
Efficacy of Intravenous Lidocaine on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy
NA trial testing Lidocaine Hydrochloride, Injectable in Primary Liver Cancer in 260 participants. Completed in 27 May 2022.
27 May 2022
Quick facts
| Lead sponsor | West China Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 260 |
| Start date | 27 February 2020 |
| Primary completion | 27 May 2022 |
| Estimated completion | 27 May 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Lidocaine Hydrochloride, Injectable — full drug profile →
- 0.9% normal saline
Conditions studied
- Primary Liver Cancer — all drugs for Primary Liver Cancer →
Sponsor
West China Hospital
Who can join
Adults 18 to 80, any sex, with Primary Liver Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients who meet the enrollment criteria will be randomized 1:1 to either the lidocaine or the placebo group. In the lidocaine group, at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. In the placebo group, the same volume of normal saline will be administered during anesthesia.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Repositioning Lidocaine as an Anticancer Drug: The Role Beyond Anesthesia.
Zhou D, Wang L, Cui Q, Iftikhar R, et al · · 2020 · cited 35× · PMID 32766241 · DOI 10.3389/fcell.2020.00565 -
Efficacy of prolonged intravenous lidocaine infusion for postoperative movement-evoked pain following hepatectomy: a double-blinded, randomised, placebo-controlled trial.
Xu Y, Ye M, Liu F, Hong Y, et al · · 2023 · cited 22× · PMID 37202261 · DOI 10.1016/j.bja.2023.03.026 -
Identifying an optimal machine learning model generated circulating biomarker to predict chronic postoperative pain in patients undergoing hepatectomy.
Hong Y, Li Y, Ye M, Yan S, et al · · 2022 · cited 6× · PMID 36684250 · DOI 10.3389/fsurg.2022.1068321 -
Efficacy of Perioperative Continuous Intravenous Lidocaine Infusion for 72 Hours on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy: Study Protocol for a Prospective Randomized Controlled Trial.
Xu Y, Ye M, Hong Y, Kang Y, et al · · 2021 · cited 6× · PMID 34880671 · DOI 10.2147/jpr.s341550 -
Safety of perioperative intravenous lidocaine in liver surgery - A pilot study.
Grassin P, Descamps R, Bourgine J, Lubrano J, et al · · 2024 · cited 1× · PMID 38919445 · DOI 10.4103/joacp.joacp_391_22
Verify or expand the search:
- PubMed search for NCT04295330
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lidocaine Hydrochloride, Injectable
Trials testing the same drug.
- NCT04992572 — Study Comparing Local/ MAC Anesthesia in Lumbar Decompression · EARLY_PHASE1 · recruiting
- NCT05492669 — Intravenous Lidocaine on Chronic Pain in Patients Undergoing Hepatectomy · Phase 2 · recruiting
- NCT05369650 — To Explore the Safety and Efficacy of Intravenous Infusion of Different Doses of Lidocaine in Patients · NA · unknown
Other recruiting trials for Primary Liver Cancer
Currently open trials in the same condition.
- NCT07437859 — Exploring the Application of 3D Bioprinting for Personalized Treatment in Primary Liver Cancer With Tumor Microenvironme · active not recruiting
- NCT07145801 — Y-90 Treatment Response Using Transarterial Radioembolization · Phase 2 · recruiting
- NCT07466602 — cfDNA Methylation for Liver Cancer Recurrence Detection · recruiting
- NCT06914648 — The Dragon PLC Trial (DRAGON-PLC) · NA · recruiting
- NCT06905015 — Stroke Volume Variation Versus Central Venous Pressure Guidance for Reducing Perioperative Blood Loss During Open Liver · NA · recruiting
Other West China Hospital trials
Trials by the same sponsor.
- NCT07583654 — Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
- NCT07583914 — Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
- NCT07492914 — Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma · Phase 2 · recruiting
- NCT07507097 — Study on the Optimal Head Position for Patients With Severe Acute Ischemic Stroke · NA · not yet recruiting
- NCT07472933 — Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04295330 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by West China Hospital
- Last refreshed: 26 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04295330.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing